Drugs / XTL6001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07205432 | Jun 2025 → Apr 2026 overdue | — | Shanghai Xitaili Biomedicine Technology co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XTL6001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07205432 ↗ |
| Action | Activate | “triple-target Glucagon-like peptide-1 receptor （GLP-1R） relevant agonist” NCT07205432 ↗ |